Guangzhou Baiyunshan Pharmaceutical Holdings | Sustainability Performance
Researches, manufactures, and markets pharmaceutical products, traditional Chinese medicines, and healthcare items. Activities include product development, large-scale manufacturing, distribution to hospitals and pharmacies, and sales under multiple healthcare brands.
1997
China
10,001+ employees
Pharmaceuticals
$10B+ in revenue
$100M - 500M in profitability
Sustainability Ranking & Industry Benchmark
#1755
Overall#39
in China#48
in PharmaceuticalsSustainability Maturity
Sustainability Intent
Overview
Environmental
Carbon emissionsEnergy consumptionWaste ManagementWater ManagementSocial
Diversity and Inclusion
CO2 scope 1 + 2
Aligned
Waste generated
Laggard
Female employees
Laggard
Carbon emissions
Reveal data for 1 credit
Industry rank: 38 out of 311
Total CO2 emissions
(CO2e tonnes)
Industry rank: 38 out of 311
Scope 1
Scope 2 location based
Scope 3 downstream
Scope 3 upstream
Industry benchmark
(adj. for revenues)
(adj. for revenues)
Renewable energy
Reveal data for 1 credit
Industry rank: Beyond Top 100
Total energy consumption
and % renewables
(MWh, % of consumption)
Industry rank: Beyond Top 100
Total energy
Share of renewable energy
Industry benchmark
Renewable electricity
Reveal data for 1 credit
Industry rank: Beyond Top 100
Total electricity consumption
and % renewables
(MWh, % of consumption)
Industry rank: Beyond Top 100
Total electricity
Share of renewable electricity
Industry benchmark
Intensity
Greenhouse gas intensity Scope 1, 2 (tCO₂e /$M)
Energy consumption (direct) intensity (MWh /$M)
Industry Benchmark
13.9
B/M 13.9
40.9
B/M 35.5
Powered by illuminem and GIST Impact
Female employees
Reveal data for 1 credit
Share of female employees (%)
25
50
75
100
Company
Benchmark
Waste
Reveal data for 1 credit
48.7K2025
Total waste generated (tonnes)
Total waste
Recovered & recycled
Not-recovered & not-recycled
Industry Benchmark
Powered by illuminem and GIST Impact
Controversy level
- Guangzhou Baiyunshan Pharmaceutical Holdings, Chinese state-owned pharma, has faced sustained Chinese NMPA enforcement scrutiny over alleged inadequate disclosure of multiple traditional Chinese medicine product quality and the contested historic 2018-2019 'Wang Lao Ji' herbal tea trademark dispute with Hong Kong's Hung To Group affecting Hong Kong-listed institutional shareholders.
Carbon emissions breakdown
Reveal data for 2 credits
| KPI | Metric | Year | |||||
|---|---|---|---|---|---|---|---|
| 2021 | 2022 | 2023 | 2024 | 2025 | Benchmark | ||
| ******* | ******* | - | - | - | ******* | ******* | ******* |
| ******* | ******* | - | - | - | ******* | ******* | ******* |
| ******* | ******* | - | - | - | ******* | ******* | ******* |
| ******* | ******* | - | - | - | ******* | ******* | ******* |
| ******* | ******* | - | - | - | ******* | ******* | ******* |
| ******* | ******* | - | - | - | ******* | ******* | ******* |
Waste management
Reveal data for 2 credits
| KPI | Metric | Year | |||||
|---|---|---|---|---|---|---|---|
| 2021 | 2022 | 2023 | 2024 | 2025 | Benchmark | ||
| ******* | ******* | - | - | - | ******* | ******* | ******* |
| ******* | ******* | - | - | - | ******* | ******* | ******* |
Water management
Reveal data for 2 credits
| KPI | Metric | Year | |||||
|---|---|---|---|---|---|---|---|
| 2021 | 2022 | 2023 | 2024 | 2025 | Benchmark | ||
| ******* | ******* | - | - | - | ******* | ******* | ******* |
| ******* | ******* | - | - | - | ******* | ******* | ******* |
